The productivity crisis in pharmaceutical R&D
We analyze the decline of R&D productivity in pharmaceuticals and its determinants. Since the molecular biology revolution, science has dramatically expanded the set of plausible therapeutic targets. However, innovation has become more difficult to achieve, and attrition rates of R&D projects have increased, especially in late-phase clinical trials. We show that the R&D productivity slowdown is associated with a higher concentration of R&D investments in high-risk domains, corresponding to unsolved therapeutic needs and unexploited biological mechanisms. We compare the strategies of European and US companies, finding differences in the composition of R&D portfolios, but no evidence of any productivity gap.
|Date of creation:||Apr 2010|
|Date of revision:|
|Contact details of provider:|| Postal: Via Cantarane, 24 - I-37129 Verona|
Phone: +39 045 802 8095
Fax: +39 045 802 8529
Web page: http://www.dse.univr.it
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:ver:wpaper:06/2010. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Michael Reiter)
If references are entirely missing, you can add them using this form.